Literature DB >> 3954251

Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees.

C M Nolan, M L Aitken, A M Elarth, K M Anderson, W T Miller.   

Abstract

The outcome of isoniazid chemoprophylaxis for tuberculosis was assessed in refugees from Southeast Asia. From July 1979 through June 1982, 2,795 tuberculin-positive refugees were prescribed isoniazid chemoprophylaxis at the time of their resettlement in King County, Washington. Through December 1983, 19 cases of active tuberculosis had arisen in those refugees. The annual incidence varied between 2.04 and 2.86 cases per 1,000 receiving treatment during the 4 yr after initiation of chemoprophylaxis (cumulative incidence, 9.66 per 1,000). Seven of the cases of tuberculosis occurring after isoniazid chemoprophylaxis were pulmonary, 1 was pulmonary and extrapulmonary (lymphatic), and 11 were extrapulmonary alone (lymphatic, 6 cases; pleural, 4 cases; soft tissue, 1 case). Fifteen of the 19 cases were culture positive, among which 8 M. tuberculosis isolates were susceptible to isoniazid and 7 were resistant. A case-control analysis showed that poor compliance, defined as taking isoniazid for 3 months or less, was associated with a sixfold increase in risk for subsequent isoniazid-susceptible tuberculosis but with no increased risk for subsequent isoniazid-resistant disease. Thus, active tuberculosis continued to occur with a low but relatively constant incidence after prescription of isoniazid chemoprophylaxis to Southeast Asian refugees. In this setting, poor compliance with chemoprophylaxis predisposed to isoniazid-susceptible, but not to isoniazid-resistant tuberculosis. There is a need to improve the approach to prevention of tuberculosis in Southeast Asian refugees.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3954251     DOI: 10.1164/arrd.1986.133.3.431

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  10 in total

1.  The health care needs of southeast asian refugees.

Authors:  J M Morse; A J Edwards; T Kappagoda
Journal:  Can Fam Physician       Date:  1988-11       Impact factor: 3.275

2.  Tuberculosis among immigrants: interval from arrival in Canada to diagnosis. A 5-year study in southern Alberta.

Authors:  R L Cowie; J W Sharpe
Journal:  CMAJ       Date:  1998-03-10       Impact factor: 8.262

3.  "Strong medicine": Cambodian views of medicine and medical compliance.

Authors:  J Shimada; J C Jackson; E Goldstein; D Buchwald
Journal:  J Gen Intern Med       Date:  1995-07       Impact factor: 5.128

4.  Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.

Authors:  S R Salpeter
Journal:  West J Med       Date:  1993-11

Review 5.  Isoniazid-resistant tuberculosis in children: a systematic review.

Authors:  Courtney M Yuen; Arielle W Tolman; Ted Cohen; Jonathan B Parr; Salmaan Keshavjee; Mercedes C Becerra
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

6.  Tuberculosis risk factors in adults in King County, Washington, 1988 through 1990.

Authors:  S E Buskin; J L Gale; N S Weiss; C M Nolan
Journal:  Am J Public Health       Date:  1994-11       Impact factor: 9.308

Review 7.  Isoniazid preventive therapy and risk for resistant tuberculosis.

Authors:  Maria Elvira Balcells; Sara L Thomas; Peter Godfrey-Faussett; Alison D Grant
Journal:  Emerg Infect Dis       Date:  2006-05       Impact factor: 6.883

Review 8.  Recent developments in treatment of latent tuberculosis infection.

Authors:  Dick Menzies; Hamdan Al Jahdali; Badriah Al Otaibi
Journal:  Indian J Med Res       Date:  2011-03       Impact factor: 2.375

9.  Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti.

Authors:  Vary Jacquet; Willy Morose; Kevin Schwartzman; Olivia Oxlade; Graham Barr; Franque Grimard; Dick Menzies
Journal:  BMC Public Health       Date:  2006-08-15       Impact factor: 3.295

10.  Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis.

Authors:  Emily A Kendall; Hamidah Hussain; Amber Kunkel; Rachel W Kubiak; Anete Trajman; Richard Menzies; Paul K Drain
Journal:  BMC Med       Date:  2021-12-14       Impact factor: 11.150

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.